

Exhibit 70

Calcijex by GCN 93140/93141 from 1/1/91-present.**Querypath**

CLM_Reimb_Amt	Drug/Brand Name	Drug NDC	Drug Manufacturer	Drug Qty Disp	CLM DOS Calendar Year
\$610.02	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	78	1991
\$231.18	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	22	1992
\$255.76	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	108	1993
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	1994
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	1995
\$13.69	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	1	1996
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	1997
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	1998
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	1999
\$274.23	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	25	2000
\$10.45	CALCIJEX 1 MCG/ML AMPUL	00074120001	ABBOTT HOSP	1	2001
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	2002
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	2003
\$0.00	CALCIJEX 1 MCG/ML AMPUL		ABBOTT HOSP	0	2004
\$212.90	CALCIJEX 1 MCG/ML AMPUL	63323073101	American Pharmacu	37	2005
\$0.00	CALCIJEX 1 MCG/ML AMPUL			0	2006
\$0.00	CALCIJEX 1 MCG/ML AMPUL			0	2007
\$1,608.23				272	

SUM(CLM_MASTER_PHARM_PD_NADJ_V.CLM_REIMBURSE_AMT) as "SUM Clm Reimb Amt",
SUM(CLM_DRUG_PD_V.CLM_DRUG_QTY) as "SUM Drug Qty Disp",
CLM_MASTER_PHARM_PD_NADJ_V.CLM_CALENDAR_YR as "Clm DOS Calendar Year",
CLM_DRUG_PD_V.DRUG_MANUFACT_NAME as "Drug Manufacturer Name",
CLM_DRUG_PD_V.CLM_NATL_DRUG_CD as "Drug NDC"

FROM

CLM_DRUG_PD_V,
CLM_MASTER_PHARM_PD_NADJ_V

WHERE

CLM_MASTER_PHARM_PD_NADJ_V.CLM_ICN = CLM_DRUG_PD_V.CLM_ICN (+) AND
CLM_MASTER_PHARM_PD_NADJ_V.CLM_DATE_PAID = CLM_DRUG_PD_V.CLM_DATE_PAID (+)

GROUP BY

CLM_MASTER_PHARM_PD_NADJ_V.CLM_CALENDAR_YR,
CLM_DRUG_PD_V.DRUG_MANUFACT_NAME,
CLM_DRUG_PD_V.CLM_NATL_DRUG_CD

ORDER BY

"Clm DOS Calendar Year",
"Drug NDC"

e

(+) AND (CLM_MASTER_PHARM_PD_NADJ_V.CLM_DATE_PAID BETWEEN '01-Jan-1991' AND '15-

-Apr-2007') AND (CLM_DRUG_PD_V.CLM_DRUG_GENERIC_CD IN('93140', '93141'))

Exhibit 71

Harvey Weintraub HIGHLY CONFIDENTIAL - UNDER PROTECTIVE ORDER August 25, 2005
Kenilworth, NJ

Page 1

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS
MDL NO. 1456
CIVIL ACTION: 01-CV-12257-PBS
Judge Patti B. Saris

x-----x

IN RE: PHARMACEUTICAL INDUSTRY:	VIDEOTAPE
AVERAGE WHOLESALE PRICE	: DEPOSITION OF:
LITIGATION	: HARVEY
_____	: WEINTRAUB

THIS DOCUMENT RELATES TO
ALL CLASS ACTIONS

x-----x

Henderson Legal Services
(202) 220-4158

Harvey Weintraub HIGHLY CONFIDENTIAL - UNDER PROTECTIVE ORDER August 25, 2005
Kenilworth, NJ

Page 22	Page 24
<p>1 Q. Would you please review that?</p> <p>2 And for the record, so that it might be</p> <p>3 easier for the judge or the jury looking at this,</p> <p>4 I'm going to read it out loud, if you just follow.</p> <p>5 "Average wholesale price, AWP, is the price</p> <p>6 at which the retailer purchases a product from the</p> <p>7 wholesaler. This price is based upon a percentage</p> <p>8 increase over the wholesaler's cost, the net cost</p> <p>9 to the wholesaler plus 16 and two-thirds percent.</p> <p>10 An increase over the wholesaler's cost, depending</p> <p>11 upon the particular wholesaler's profit margin and</p> <p>12 the volume that the retailer does with the</p> <p>13 wholesaler. The actual price that the retailer</p> <p>14 pays the wholesaler is usually less than 16 and</p> <p>15 two-thirds percent due to the competition for</p> <p>16 business among wholesalers."</p> <p>17 Did I read that correctly, sir?</p> <p>18 A. Yes. You did.</p> <p>19 Q. Okay. Is that a definition or</p> <p>20 explanation of AWP that you're familiar with?</p> <p>21 A. I don't know that it's a definition, it's a</p> <p>22 practice for which I'm familiar with.</p>	<p>1 When did you begin to do any work with or</p> <p>2 for Warrick Pharmaceuticals?</p> <p>3 A. Sometime in early 1993.</p> <p>4 Q. And 1993, was that when Warrick was</p> <p>5 actually created?</p> <p>6 A. I believe it was.</p> <p>7 Q. And as we sit here today, do you</p> <p>8 have any responsibilities, contracts or positions</p> <p>9 with any Schering Plough subsidiary or Warrick?</p> <p>10 A. Yes. I do.</p> <p>11 Q. Okay. Would you describe what</p> <p>12 those responsibilities or contracts are?</p> <p>13 A. At this time I am a consultant for Schering</p> <p>14 Corporation.</p> <p>15 Q. And is that pursuant to a written</p> <p>16 contract?</p> <p>17 A. Yes. It is.</p> <p>18 Q. And if you could just tell me the</p> <p>19 term of the contract, when it began and if it is</p> <p>20 for a term or a period?</p> <p>21 A. It's for calendar 19 -- calendar 2005.</p> <p>22 Q. And does that consultancy contract</p>
Page 23	Page 25
<p>1 Q. And is this a working definition</p> <p>2 that you used at Schering-Plough?</p> <p>3 A. For the most part. The first sentence that</p> <p>4 says AWP is the price at which a retailer</p> <p>5 purchases a product is a fact nullified by the</p> <p>6 remainder of it. It's not the price that the</p> <p>7 retailer purchases the product. It's really a</p> <p>8 sticker price.</p> <p>9 Q. And is it one of the utilities of</p> <p>10 AWP is for reimbursement by third party payers?</p> <p>11 MR. KAUFMAN: Object to the form of</p> <p>12 the question.</p> <p>13 You may answer.</p> <p>14 A. In some cases, yes.</p> <p>15 Q. And that would also include</p> <p>16 Medicare and Medicaid pricing at different times</p> <p>17 throughout the past?</p> <p>18 MR. KAUFMAN: Objection. You may</p> <p>19 answer.</p> <p>20 A. For certain products I believe so.</p> <p>21 Q. Now, after, well, let me just</p> <p>22 strike that.</p>	<p>1 with Schering Corporation entail any work relative</p> <p>2 to Warrick Pharmaceuticals?</p> <p>3 A. Not at this point, no.</p> <p>4 Q. If you can, just tell me generally</p> <p>5 what else does your consultancy with Schering</p> <p>6 Corporation involve at this time?</p> <p>7 A. Generally, working for the Law Department</p> <p>8 on a retainer basis providing institutional</p> <p>9 memory, I guess would be the best way to phrase</p> <p>10 it.</p> <p>11 Q. And would that position be true for</p> <p>12 the entire year so far, 2005?</p> <p>13 A. Yes. Yes. It would.</p> <p>14 Q. Prior to -- well, for 2004, were</p> <p>15 you under contract or have any employment with</p> <p>16 Schering-Plough?</p> <p>17 A. I was under contract as a consultant to</p> <p>18 Warrick Pharmaceuticals.</p> <p>19 Q. And what was the term for that</p> <p>20 consultancy contract with Warrick?</p> <p>21 A. It was on a one year basis renewable.</p> <p>22 Q. And when did the first consultancy</p>

7 (Pages 22 to 25)

Henderson Legal Services
(202) 220-4158

Exhibit 72

Jerome A. Sherman

HIGHLY CONFIDENTIAL
Boston, MA

July 7, 2005

Page 1

HIGHLY CONFIDENTIAL TRANSCRIPT

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

IN RE:) MDL NO. 1456
PHARMACEUTICAL INDUSTRY) Civil Action No. 01-CV-12257-PBS
AVERAGE WHOLESALE PRICE)
LITIGATION)
)

VIDEOTAPED DEPOSITION OF JEROME A.

SHERMAN, called as a witness on behalf of
the Plaintiffs, pursuant to the applicable
provisions of the Federal Rules of Civil
Procedure, before Jeanette N. Maracas,
Registered Professional Reporter and Notary
Public in and for the Commonwealth of
Massachusetts, at the Offices of Ropes &
Gray, LLP, One International Place, Boston,
Massachusetts, on Thursday, July 7, 2005,
commencing at 9:12 a.m.

Jerome A. Sherman

HIGHLY CONFIDENTIAL
Boston, MA

July 7, 2005

<p style="text-align: right;">Page 18</p> <p>1 A. Yes, he's a Schering-Plough employee. 2 Q. Do you know what his position or title is 3 with Schering-Plough? 4 A. No, I don't. 5 Q. Does Warrick Pharmaceuticals, Inc. currently 6 have any employees? 7 A. I don't know. I don't know how that works. 8 Q. Now, where are you officed? 9 A. In Union, New Jersey. 10 Q. Where is Mr. Gough officed? 11 A. Arizona. 12 Q. And what kind of -- is it a Schering-Plough 13 facility where he's officed? 14 A. I believe he works out of his home. 15 Q. And Mr. Graf, where is he officed? 16 A. In St. Louis, Missouri. 17 Q. Does he work out of a Schering-Plough 18 facility or is he out of his house as well? 19 A. Out of his home. 20 Q. Who is Mr. Harvey Weintraub? 21 A. Harvey Weintraub is a consultant for 22 Warrick, or had been.</p>	<p style="text-align: right;">Page 20</p> <p>1 A. He was president of Warrick. 2 Q. Do you know when he ended being president 3 of Warrick? 4 A. Approximately a year ago. 5 Q. To your knowledge, is he providing any 6 services or employment to Schering-Plough 7 at this time? 8 A. Not to my knowledge. 9 Q. When is the last time you actually talked 10 with Raymond Kapur? 11 A. Probably just before he left. 12 Q. Did you ever talk with Mr. Kapur concerning 13 this litigation? 14 A. No, I did not. 15 Q. When was the last time you talked with 16 Richard Zahn? 17 A. Sometime approximately 12 years ago. 18 Q. That would be either on the phone or in 19 person, same answer? 20 A. Correct. 21 Q. Mr. Sherman, have you ever been in any 22 Warrick offices in Niles, Illinois?</p>
<p style="text-align: right;">Page 19</p> <p>1 Q. Is Mr. Weintraub no longer a consultant 2 for Warrick? 3 A. Correct. 4 Q. And when did he end or stop consultancy 5 with Warrick? 6 A. January of '05. 7 Q. Do you know whether or not Mr. Weintraub 8 is providing any consulting services to 9 Schering-Plough at this time? 10 A. I believe he does. 11 Q. Who is Richard Zahn? 12 A. He was president. I believe his title was 13 president of Schering Labs. 14 Q. Is Mr. Zahn still with the Schering-Plough 15 Corporation? 16 A. No. 17 Q. Do you know when he left? 18 A. I don't remember the exact timing of it. 19 Q. And who is Raymond, or I believe it's Kapur. 20 Is that how you pronounce the last name? 21 A. Correct. 22 Q. Who is Raymond Kapur?</p>	<p style="text-align: right;">Page 21</p> <p>1 A. No. 2 Q. Have you ever been in any Warrick 3 Pharmaceuticals offices in Reno, Nevada? 4 A. No. 5 Q. In connection with your testimony today, 6 we will be discussing some terms that I 7 just want to make sure that we're on the 8 same page with as we go forward, and one 9 of those terms, of course, is AWP or 10 average wholesale price. Do you understand 11 that term? 12 A. Yes. 13 Q. What is your understanding of AWP? 14 A. AWP to me means a benchmark or just a 15 benchmark price. 16 Q. What is your understanding, a benchmark, 17 how is that used in your industry? 18 MR. CHRISTOFFERSON: Objection. You 19 may answer. 20 A. My understanding is it's used for 21 reimbursement. 22 Q. When you say reimbursement, does that mean</p>

6 (Pages 18 to 21)

Jerome A. Sherman

HIGHLY CONFIDENTIAL
Boston, MA

July 7, 2005

Page 22	Page 24
<p>1 reimbursement from third-party payers such</p> <p>2 as insurance companies or public programs</p> <p>3 such as Medicare, Medicaid?</p> <p>4 A. Those payers, as well as -- those payers</p> <p>5 use that, I believe, as well as MAC and some</p> <p>6 other benchmark's baseline.</p> <p>7 Q. Is it your understanding that those</p> <p>8 benchmarks change over time from time to</p> <p>9 time? Is that a fair statement?</p> <p>10 MR. CHRISTOFFERSON: Objection. You</p> <p>11 may answer.</p> <p>12 A. I'm not aware of that.</p> <p>13 Q. Now, in connection with your status as a</p> <p>14 registered pharmacist, are you familiar</p> <p>15 with any industry publications that are</p> <p>16 used for pricing services?</p> <p>17 A. Yes.</p> <p>18 Q. Would you identify those that you're familiar</p> <p>19 with.</p> <p>20 A. Redbook, Price Alert. That's all that I'm</p> <p>21 aware of.</p> <p>22 Q. Now, from time to time over the past -- well,</p>	<p>1 may answer.</p> <p>2 A. I believe we do.</p> <p>3 Q. I'm going to be marking a number of documents</p> <p>4 or having the court reporter mark the</p> <p>5 documents and just ask questions. On each</p> <p>6 document, what I'll do is give you an</p> <p>7 opportunity to look at the document and then</p> <p>8 I'll just ask my questions.</p> <p>9 A. Sure.</p> <p>10 Q. Is that fair enough? And if at any time --</p> <p>11 of course, you've had your deposition</p> <p>12 taken before. If you don't understand</p> <p>13 my questions, please let me know and I'll</p> <p>14 try to clear them up, if that's at all</p> <p>15 possible.</p> <p>16 A. Sure.</p> <p>17 MR. CHRISTOFFERSON: Just for the</p> <p>18 record, I want to make the point that we're</p> <p>19 designating this transcript as highly</p> <p>20 confidential pursuant to the protective</p> <p>21 order in this litigation.</p> <p>22 Q. Before I get on the documents, let me ask</p>
Page 23	Page 25
<p>1 I believe you've been a registered pharmacist</p> <p>2 since 1962. Do you use or refer to any of</p> <p>3 those, either Redbook or Price Alert?</p> <p>4 MR. CHRISTOFFERSON: Objection. I</p> <p>5 think he said he's not been since 1962, but</p> <p>6 you may answer the question.</p> <p>7 A. Yeah, can I clear that up?</p> <p>8 Q. Sure.</p> <p>9 A. I'm not a pharmacist by trade right now. I</p> <p>10 have my license, but I don't practice</p> <p>11 pharmacy.</p> <p>12 Q. Say for the Redbook publication, is that a</p> <p>13 publication that you or the people in your</p> <p>14 office keep available for reference in your</p> <p>15 office in Union?</p> <p>16 A. I don't.</p> <p>17 Q. Are there Redbooks available to you if you</p> <p>18 should choose to look at one?</p> <p>19 A. If I choose to look at one, I can find one.</p> <p>20 Q. Does Warrick Pharmaceuticals subscribe to</p> <p>21 the publication, Redbook?</p> <p>22 MR. CHRISTOFFERSON: Objection. You</p>	<p>1 a few general questions. As a national</p> <p>2 director for Warrick Pharmaceuticals, who</p> <p>3 are the customers that you call on? Who are</p> <p>4 your accounts?</p> <p>5 A. You want them all?</p> <p>6 Q. If you can give them in categories, broad</p> <p>7 categories, and then we can break them down,</p> <p>8 if necessary. But, generally, what are</p> <p>9 the categories or class of trade that you</p> <p>10 call on for Warrick Pharmaceuticals?</p> <p>11 A. Wholesalers, chains and generic distributors.</p> <p>12 Q. Now, on the category of chains, would that</p> <p>13 include retail pharmacies?</p> <p>14 A. Chains, the chains' headquarters.</p> <p>15 Q. Go ahead and tell me who are the chains.</p> <p>16 Those are chains pharmacies?</p> <p>17 A. Yes.</p> <p>18 Q. And who are the chains pharmacies that you</p> <p>19 call on?</p> <p>20 A. CVS, Rite-Aid, Brooks-Eckerd, to name three</p> <p>21 big ones.</p> <p>22 Q. Those are your largest chain pharmacy</p>

7 (Pages 22 to 25)

Jerome A. Sherman

HIGHLY CONFIDENTIAL
Boston, MA

July 7, 2005

Page 122	Page 124
<p>1 is that correct?</p> <p>2 MR. CHRISTOFFERSON: Objection. You</p> <p>3 may answer.</p> <p>4 A. I haven't seen the AWP on those documents</p> <p>5 for very long time.</p> <p>6 Q. When was the last time that you saw a</p> <p>7 document notifying a price change where</p> <p>8 AWP was not listed?</p> <p>9 A. Repeat that, please.</p> <p>10 Q. You said that you hadn't seen AWP on a</p> <p>11 price change document in a very long time.</p> <p>12 When did you start sending out price change</p> <p>13 notices without AWP on it?</p> <p>14 A. I don't remember when that occurred.</p> <p>15 (Exhibit Sherman 030 marked for</p> <p>16 identification.)</p> <p>17 Q. Mr. Sherman, you've been handed a document</p> <p>18 that has been marked Exhibit Sherman 030?</p> <p>19 A. Yes.</p> <p>20 Q. And this is a price change notification</p> <p>21 from you to one of your accounts; is that</p> <p>22 correct?</p>	<p>1 A. Yes.</p> <p>2 Q. And also, if the direct price is subject to</p> <p>3 any rebates that would result in a decreased</p> <p>4 price per unit, that would also result in a</p> <p>5 spread; is that correct?</p> <p>6 MR. CHRISTOFFERSON: Objection. You</p> <p>7 may answer.</p> <p>8 A. Yes.</p> <p>9 Q. Now, having looked at this last exhibit,</p> <p>10 which is in May of -- apparently, effective</p> <p>11 date of the price change in May of 2000,</p> <p>12 does that help or refresh your memory in</p> <p>13 any way as to when AWP was discontinued</p> <p>14 as an item on a price change notice?</p> <p>15 A. No, it doesn't. It was, obviously,</p> <p>16 subsequent to this time frame.</p> <p>17 Q. Mr. Sherman, are you familiar with a term,</p> <p>18 "nominal pricing," for purposes of either</p> <p>19 contracts or for selling product on behalf</p> <p>20 of Warrick Pharmaceuticals?</p> <p>21 A. I've heard the term.</p> <p>22 Q. What is your understanding of nominal</p>
Page 123	Page 125
<p>1 A. Yes.</p> <p>2 Q. And the effective date on this price change</p> <p>3 is, appears to be May 8 of 2000. Is that</p> <p>4 how you read this document?</p> <p>5 A. Yes.</p> <p>6 Q. So as recent as, or at least the year 2000,</p> <p>7 AWP was still being reported or shown</p> <p>8 on price change notifications; is that</p> <p>9 correct?</p> <p>10 MR. CHRISTOFFERSON: Objection. You</p> <p>11 may answer.</p> <p>12 A. Yes.</p> <p>13 Q. With regard to the spread, the difference</p> <p>14 between the AWP and the direct price as</p> <p>15 shown on this, is it not correct that as</p> <p>16 the AWP -- strike that.</p> <p>17 Would you agree that where the AWP</p> <p>18 remains the same and the direct price is</p> <p>19 decreased, that there's an increase in the</p> <p>20 spread?</p> <p>21 MR. CHRISTOFFERSON: Objection. You</p> <p>22 may answer.</p>	<p>1 pricing?</p> <p>2 A. It's a very low price.</p> <p>3 Q. Have you ever used nominal pricing in</p> <p>4 connection with any of your transactions</p> <p>5 with your accounts?</p> <p>6 A. Not that I can ever recall, no.</p> <p>7 Q. Is nominal pricing used as a, or used in</p> <p>8 contracting or offering prices by Warrick</p> <p>9 Pharmaceuticals today?</p> <p>10 MR. CHRISTOFFERSON: Objection. You</p> <p>11 may answer.</p> <p>12 A. Not that I'm aware of, no.</p> <p>13 MR. McNEELY: If we can go off the</p> <p>14 record.</p> <p>15 MR. CHRISTOFFERSON: Yes.</p> <p>16 VIDEOGRAPHER: The time is 1:29. We</p> <p>17 are off the record.</p> <p>18 (Discussion off the record)</p> <p>19 VIDEOGRAPHER: The time is 1:32.</p> <p>20 We're back on the record.</p> <p>21 BY MR. McNEELY:</p> <p>22 Q. Mr. Sherman, with regard to the Warrick</p>

32 (Pages 122 to 125)

Exhibit 73

PAGE 2

097837000523

WESTERN
UNION

MAILGRAM

UNITED STATES
POSTAL SERVICE

KEY PRODUCTS

	NDC 0085	NDP	AWP
INSPIREASE REPLACEMENT MOUTHPIE	4604-02	\$ 14.81	\$ 17.77
K-DUR 10 TABLETS 10MEQ 100'S	0263-01	26.75	32.10
K-DUR 10 TABLETS 10MEQ 100'S UD	0263-81	27.71	33.25
K-DUR 20 TABLETS 20 MEQK 100'S	0787-01	48.72	58.46
K-DUR 20 TABLETS 20 MEQK 500'S	0787-06	241.70	290.04
K-DUR 20 TABLETS 20 MEQK 1000	0787-10	475.24	570.29
K-DUR 20 TABS 20 MEQK 100'S UD	0787-81	52.81	63.37
LOTTRISONE LOTION	0809-01	37.61	45.13
MIRADON TABLETS 50MG 100'S	0795-05	45.91	55.09
NAQUA TABLETS 4MG 100'S	0547-03	70.89	85.07
NITRO-DUR T.I.S. 0.8 MG/HR 30'S	0019-30	57.17	68.60
NITRO-DUR T.I.S. 0.8 MG/HR INST	0019-35	57.17	68.60
NITRO-DUR T.I.S. 0.1 MG/HR 30'S	3305-30	46.34	55.61
NITRO-DUR T.I.S. 0.1 MG/HR INST	3305-35	46.34	55.61
NITRO-DUR T.I.S. 0.2 MG/HR 30'S	3310-30	47.04	56.45
NITRO-DUR T.I.S. 0.2 MG/HR INST	3310-35	47.04	56.45
NITRO-DUR T.I.S. 0.3 MG/HR 30'S	3315-30	52.69	63.23
NITRO-DUR T.I.S. 0.3 MG/HR INST	3315-35	52.69	63.23
NITRO-DUR T.I.S. 0.4 MG/HR 30'S	3320-30	52.69	63.23
NITRO-DUR T.I.S. 0.4 MG/HR INST	3320-35	52.69	63.23
NITRO-DUR T.I.S. 0.6 MG/HR 30'S	3330-30	57.17	68.60
NITRO-DUR T.I.S. 0.6 MG/HR INST	3330-35	57.17	68.60
NORMODYNE INJ 40 ML MULTI-DOSE	0362-06	73.21	87.85
NORMODYNE INJ 20 ML MULTI-DOSE	0362-07	37.79	45.35
NORMODYNE SYRINGES 20 MG 4 ML	0362-08	16.31	19.57
NORMODYNE INJ SYRINGE 40 MG	0362-09	24.50	29.40
NORMODYNE TABLETS 100 MG 100'S	0244-04	52.05	62.46
NORMODYNE TABLETS 100 MG 500'S	0244-05	246.95	296.34
NORMODYNE TABLETS 100 MG 1000'S	0244-07	455.40	546.48
NORMODYNE TABLETS 100MG 100S UD	0244-08	55.27	66.32
NORMODYNE TABLETS 200 MG 100'S	0752-04	73.83	88.60
NORMODYNE TABLETS 200MG 500'S	0752-05	350.77	420.92
NORMODYNE TABLETS 200MG 100S UD	0752-08	77.05	92.46
NORMODYNE TABLETS 300MG 100'S	0438-03	98.22	117.86
NORMODYNE TABLETS 300MG 500'S	0438-05	466.42	559.70
NORMODYNE TABLETS 300MG 100S UD	0438-06	101.47	121.76
OPTIMINE TABLETS 1MG 100'S	0282-03	105.00	126.00
PROVENTIL HFA INH AEROSOL 6.7G	1132-01	28.23	33.88
PROVENTIL INHALER 17 G	0614-02	29.31	35.17
VANCERIL INHALER 16.8G	0736-04	38.77	46.52

HIGHLY
CONFIDENTIAL

FDB-AWP 03930

To reply by Mailgram Message, see reverse side for Western Union's toll-free number.

PAGE 3

097837000523

WESTERN
UNION

MAILGRAM

UNITED STATES
POSTAL SERVICE

ONCOLOGY PRODUCTS

	NDC 0085	NDP	AWP
EULEXIN CAPSULES 125 MG 100'S	0525-03*	\$ 211.53*	\$ 253.84
EULEXIN CAPSULES 125 MG 500'S	0525-05*	997.84	1,197.41
EULEXIN CAPSULES 125 MG 180'S	0525-06*	359.16*	430.99
TEMODAR CAPSULES 20 MG 5'S	1244-01*	111.49*	133.79
TEMODAR CAPSULES 20 MG 20'S	1244-02*	445.96*	535.15
TEMODAR CAPSULES 5 MG 5'S	1248-01*	27.87*	33.44
TEMODAR CAPSULES 5 MG 20'S	1248-02*	111.49*	133.79
TEMODAR CAPSULES 250 MG 5'S	1252-01*	1,393.63*	1,672.36
TEMODAR CAPSULES 250 MG 20'S	1252-02*	5,574.52*	6,689.42
TEMODAR CAPSULES 100 MG 5'S	1259-01*	557.45*	668.94
TEMODAR CAPSULES 100 MG 20'S	1259-02*	2,229.81*	2,675.77

KENILWORTH PRODUCTS

	NDC 0085	NDP	AWP
DIPROSONE CREAM 0.05% 15 GM	0853-02*	\$ 24.49*	\$ 29.39*
DIPROSONE CREAM 0.05% 45 GM	0853-03*	44.90*	53.88
DIPROSONE LOTION 0.05% 20ML	0028-04*	30.12*	36.14
DIPROSONE LOTION 0.05% 60 ML	0028-06*	59.29*	71.15
ESTINYL TABLETS 0.02 MG 100'S	0298-03*	35.15*	42.18
ESTINYL TABLETS 0.02MG 250'S	0298-06*	82.63*	99.16
ESTINYL TABLETS 0.05 MG 100'S	0070-03*	59.20*	71.04
ESTINYL TABLETS 0.05 MG 250'S	0070-06*	138.19*	165.83
FULVICIN P/G TABLETS 125 MG	0228-03*	50.64*	60.77
FULVICIN P/G TABLETS 165 MG	0654-03*	73.12*	87.74
FULVICIN P/G TABLETS 250 MG	0507-03*	99.36*	119.23
FULVICIN P/G TABLETS 330 MG	0352-03*	126.18*	151.42
FULVICIN U/F TABS 250 MG 60'S	0948-03*	51.84*	62.21
FULVICIN U/F TABS 250 MG 250'S	0948-06*	204.54*	245.45
FULVICIN-U/F TABS 500 MG 60'S	0496-03*	82.80*	99.36
FULVICIN-U/F TABS 500 MG 250'S	0496-06*	326.58*	391.90
GARAMYCIN CREAM 0.1% 15 GM	0008-05*	20.11*	24.13
GARAMYCIN INJ VIAL 80 MG 25/2ML	0069-04*	126.14*	151.37
GARAMYCIN OPHTHALMIC OINT 3.5GM	0151-05*	18.20*	21.84
GARAMYCIN OPHTHALMIC SOLUT 5 ML	0899-05*	18.20*	21.84
LOTRIMIN CREAM 1% 15GM	0613-02*	13.51*	16.21
LOTRIMIN CREAM 1% 45GM	0613-04*	27.81*	33.37
LOTRIMIN CREAM 1% 30GM	0613-05*	22.94*	27.53
LOTRIMIN LOTION 1% 30 ML	0707-02*	25.88*	31.06
LOTRIMIN SOLUTION 1% 10 ML	0182-02*	11.91*	14.29
LOTRIMIN SOLUTION 1% 30 ML	0182-04*	24.75*	29.70

HIGHLY
CONFIDENTIAL

FDB-AWP 03931

To reply by Mailgram Message, see reverse side for Western Union's toll-free number.

PAGE 4

097837000523



KENILWORTH PRODUCTS

	NDC 0085	NDP	AWP
POLARAMINE TABLETS 2MG 100'S	0820-03	\$ 45.85	\$ 55.02
PROVENTIL REPETABS 4 MG 100S	0431-02	73.16	87.79
PROVENTIL REPETABS 4 MG 500S	0431-03	354.92	425.90
PROVENTIL REPETABS 4 MG 100S UD	0431-04	91.64	109.97
PROVENTIL SOLUTION 25X1ML	0209-01	42.73	51.28
PROVENTIL SOLUTION 20 ML	0208-02	18.75	22.50
SOLGANAL SUSPENSION 50MG/ML	0460-03	139.75	167.70
TRILAFON INJECTION 5MG/ML	0012-04	626.00	751.20
TRINALIN REPETABS TABLETS 100'S	0703-04	109.90	131.88

SINCERELY,

FRANK J. DILASCIA, RPH
V.P., TRADE SALES & PHARM DEVELOPMENT

MGMCOMP 20:12 EST

HIGHLY
CONFIDENTIAL

FDB-AWP 03932

To reply by Mailgram Message, see reverse side for Western Union's toll-free number.

Exhibit 74

Schering LABORATORIES
TELEFAX TRANSMITTAL COVER SHEET

TO:	<i>Lna</i>
COMPANY NAME:	<i>First Data Bank</i>
FROM:	<i>Peter Kamins</i>
TELEPHONE #	<i>(908) 298-4952</i>
TELEFAX #:	<i>(908) 298-2436</i>
TOTAL # OF PAGES (including this page):	<i>3</i>

Schering Laboratories
Trade Sales-K-5-2/B-6
2000 Galloping Hill Road
Kenilworth, NJ 07033

Per your request

FAXMASTER.DOC

HIGHLY
CONFIDENTIAL

FDB-AWP 03988

SCHERING LABORATORIES
GALLOPING HILL ROAD
KENILWORTH, N.J. 07033

**WESTERN
UNION MAILGRAM**



UNITED STATES
POSTAL SERVICE

090950001367 12/13/00
BM16634

SOF1 - SOFA

1111 Bayhill Dr Ste 350 -
San Bruno CA 94066-3056

Attn Kathy Gutesell
Medi-Span, Inc
First Databank
1111 Bayhill Dr Ste 350 -
San Bruno CA 94066-3056

DEAR CUSTOMER,

EFFECTIVE WEDNESDAY, DECEMBER 13, 2000 AT 5:00 PM EDST, PRICES FOR THE FOLLOWING SCHERING PRODUCTS WERE INCREASED. ALL ORDERS RECEIVED AFTER 5:00 PM EDST, WEDNESDAY, DECEMBER 13, 2000 WILL BE BILLED AT THE NEW PRICES. A PRICE PROTECTED ORDER AND A CURRENT PRICE LIST WILL BE SENT TO YOUR BUYER SHORTLY.

ACS PRODUCTS	NDC 0085	NDP	AWP
INTEGRILIN 75MG/10ML VIAL	1136-01	\$148.82	\$178.58
INTEGRILIN 20MG/10ML BOLUS VIAL	1177-01	47.63	57.16
INTEGRILIN 20MG/10ML VIAL	1177-02	396.79	476.15

SINCERELY,

FRANK J. DILASCIA, RPH
V.P., TRADE SALES & PHARM DEVELOPMENT

MGMCOMP 20:29 EST

**HIGHLY
CONFIDENTIAL**

FDB-AWP 03990

To reply by Mailgram Message, see reverse side for Western Union's toll-free number.

Exhibit 75



7500 North Natchez Avenue, Niles, Illinois 60714-3804 • Telephone 1 800 547-3869

December 29, 1995

Mr. Mukesh Mehla
(Redbook)
Medical Economics Company
5 Paragon Drive
Montvale NJ 07645-1742

Dear Mr. Mehla:

Please list the following newly introduced Warrick Pharmaceuticals product in your pricing guide or file, effective immediately. This product is a generic to Proventil (®) Inhaler and is "A" rated.

PRODUCT	PACKAGE SIZE	NDC#	AWP
Albuterol, USP Inhalation Aerosol	17 g	59930-1560-1	\$21.41
Albuterol, USP Inhalation Aerosol Refill	17 g	59930-1560-2	\$19.79

Thank you for your prompt attention to this matter.

If you have any questions regarding Warrick Pharmaceuticals or any of our products, please do not hesitate to contact me at 908-629-3016.

Sincerely,

Harvey J. Weintraub
Harvey J. Weintraub

CONFIDENTIAL
WPX0007697

WAR0007634
Highly Confidential

Exhibit 76



7500 North Natchez Avenue, Niles, Illinois 60714-3804 • Telephone 1 800 547-3869

CONFIDENTIAL

February 23, 1995

Ms. Beth Rader
Price Alert
First Databank
1111 Bayhill Drive
Suite 350
San Bruno CA 94068

Dear Ms. Rader:

Effective Friday, February 24, 1995, at 5:00 p.m., the price of Warwick Albuterol
Solution 0.5% 20 mL will increase as follows:

	<u>NDC</u> <u>59930-</u>	<u>AWP</u>
Albuterol Solution 0.5% 20 mL	1515-04	\$13.95

Sincerely,

Harvey J. Weintraub
Harvey J. Weintraub

WP00001559A

WAR0024086
Highly Confidential

Exhibit 77

SCHERING LABORATORIES

GALLOPING HILL ROAD

KENILWORTH, N.J. 07033

TELEPHONE: (908) 298-4000

DEAR CUSTOMER,
EFFECTIVE THURSDAY, JANUARY 10, 2002 AT 05:00 PM EDT, PRICES FOR THE
FOLLOWING SCHERING PRODUCTS WERE INCREASED. ALL ORDERS
RECEIVED AFTER 05:00 PM EDT, THURSDAY, JANUARY 10, 2002 WILL BE
BILLED AT THE NEW PRICES.

A CURRENT PRICE LIST WILL BE SENT TO YOUR BUYER SHORTLY.
A PRICE PROTECTED ORDER WILL BE OFFERED IN MARCH.

ACS PRODUCTS	NDC 0085	NDP	AWP
INTEGRILIN 0.75MG/ML 10ML	1136-01	\$ 162.50	\$ 195.00
INTEGRILIN 2MG/ML 10ML BOLUS	1177-01	\$ 52.00	\$ 62.40
INTEGRILIN 2MG/ML 10ML VIAL	1177-02	\$ 433.31	\$ 519.97

SINCERELY,

FRANK J. DILASCIA, RPH
V.P., TRADE SALES & PHARM DEVELOPMENT

Highly Confidential

SFF0057742

Exhibit 78



12125 Moya Boulevard, Reno, Nevada 89506-2600 • Telephone 1 800 647-3869

November 18, 1997

Mr. Jacob Blatt
Vice President, Generic Sales
Merck-Medco Managed Care
100 Summit Avenue
Montvale, NJ 07645-1753

Via Telefax No. 201-782-7723

Dear Jacob:

As per our discussion today, Warrick pricing for Albuterol Solution for Inhalation 0.5%, 20 mL is as follows:

	Warrick Number	Warrick Price	Medco Price
Albuterol Solution 20mL	59930-1515-04	\$14.99	\$3.95

Sincerely,

A handwritten signature in cursive script, appearing to read 'Harvey'.

Harvey J. Weintraub

HJW:ar

s:\Warrick\Harvey\111897

Highly Confidential

SH0173547

Exhibit 79

September 21, 1995

Mr. John Ziebell
Pharmaceutical Buyer
Walgreen Co.
200 Wilmot Road
Deerfield IL 60015

Dear John:

Effective Thursday, September 21, 1995, at 5:00 p.m., the AWP price of Albuterol Sulfate, USP Solution for Inhalation, 0.5%, 20 mL was increased 7.5%. AWP and Direct Pricing is now as follows:

Product	Pkg. Size	NDC 59930	AWP	Direct
Albuterol Sulfate, USP Solution for Inhalation 0.5%	20 mL	59930-1515-4	\$14.99	\$ 9.00

Future purchases of Albuterol Solution 20 mL will be invoiced at the direct price, less an instant rebate, off invoice, of 23%. Your net invoice price will be \$6.93. Additionally, you will continue to receive your current rebate.

A price-protected order form, for up to your average monthly purchase of Albuterol Solution 20 mL, will be sent to you shortly.

Sincerely,

Al Graf
National Sales Director

SPW013821
HIGHLY CONFIDENTIAL